Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 272.50
Bid: 270.00
Ask: 275.00
Change: 30.00 (12.37%)
Spread: 5.00 (1.85%)
Open: 262.50
High: 272.50
Low: 255.00
Yest. Close: 242.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Faron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee

Wed, 9th Oct 2019 14:05

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee on Wednesday, from the ongoing dose escalation study from part 1 of the MATINS trial.
The AIM-traded firm explained that the phase 1 and 2 MATINS clinical trial was investigating the tolerability, safety and efficacy of 'Clevegen', its wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour-associated macrophages (TAM), in selected metastatic or inoperable solid tumours.

It said the study data monitoring committee had reviewed the safety data of all treated 11 patients and associated biomarker analyses, and the company had received advice to continue the study as planned with some notes.

Those notes included confirmation that Clevegen had a "good tolerability" across all dosing levels, with no dose limiting toxicity observed, and a maximally tolerated dose had not been reached.

Immune activation was observed in all 11 subjects measured following treatment with Clevegen, and was observed as increased circulating CD8+ T cells and CD8+/CD4+ ratio, decreased regulatory T-cells, or a "substantial increase" in mobile natural killer cells in the blood.

In addition, an increase in circulating B-cells was observed during cycles three and four of the treatment, which Faron said was an "essential part" of complete adaptive immune response.

The data monitoring committee also observed that lower doses could potentially induce a stronger immune response than the higher doses.

As a result, the committee proposed a new test dosing concentration of 0.1 mg/kg instead of a higher concentration of 20 mg/kg, which had previously been considered.

Faron said that was most evident in the activation of natural killer cells - the "first line of defence" of the immune system.

The firm said it would adopt the data monitoring committee's advice, and had decided to expand part 1 to around 30 patients in total to determine optimal dosing before moving to part 2.

It said it expected that at the conclusion of part 1, five patients would have been treated in each dose level cohort.

Now that a safe dose range had been confirmed, Faron said it believed that the remaining patients for the trial could be recruited "relatively quickly".

The expansion had no impact on US Investigational New Drug filing, the board confirmed, which it said was progressing as it had previously announced.

"We are encouraged by the guidance given by the MATINS study data monitoring committee," said Faron chief executive officer Markku Jalkanen.

"Good safety was the first priority of Part I and now we have obtained that status.

"We are also extremely happy to see that FP-1305 is very active at low doses and that the highest dose may not be the optimal."

Dr Jalkanen said the company believed it could recruit those extra patients rapidly, to obtain additional data to select the optimal dose for expansion cohorts.

"If the optimal dose really is between 0.1 and 1.0 mg/kg, it provides an unusually high safety margin for stand-alone Clevegen treatment or in combination with other cancer therapies."

More News

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

6 Feb 20 14:17

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

27 Jan 20 11:22

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

13 Jan 20 11:54

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

30 Dec 19 15:39

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

30 Dec 19 10:56

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

11 Dec 19 13:42

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

11 Dec 19 10:45

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

29 Nov 19 10:23

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

28 Nov 19 11:56

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

21 Nov 19 12:56

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

8 Nov 19 10:30

Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress

Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress

7 Nov 19 17:59

LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week

LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week

1 Nov 19 16:58

Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge

Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge

1 Nov 19 15:32

Faron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee on Wednesday, from the ongoing dose escalation study from part 1 of the MATINS trial.

9 Oct 19 14:05

Login to your account

Don't have an account? Click here to register.